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We showed that the αLβ2 integrin with the non-functional mutation G150D cannot be induced with Mg/
EGTA to express the mAb KIM127 epitope, which reports the leg-extended conformation. We extended
the study to the αIIbβ3, an integrin without an αI domain. The equivalent mutation, i.e. G161D, also
resulted in an expressible, but non-adhesive αIIbβ3 integrin. An NMR study of synthetic peptides
spanning the α1-α1′ helix of the β3 I domain shows that both wild-type and mutant peptides are α-
helical. However, whereas in the wild-type peptide this helix is continuous, the mutant presents a dis-
continuity, or kink, precisely at the site of mutation G161D. Our results suggest that the mutation may
lock integrin heterodimers in a bent conformation that prevents integrin activation via conformational
extension.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Integrin heterodimers are type-1 transmembrane glycoproteins
which mediate ﬁrm adhesion between cells and between cells and
the extracellular matrix. Each integrin is a non-covalently asso-
ciated heterodimer of one α and one β subunit [1]. The integrins
can be classiﬁed into two types depending on the presence of an I
domain (αI) in α subunit head region. In human, nine out of 18 α
subunits contain the αI domain. When present, the αI is the major
ligand binding domain. When absent, ligands will bind to a site at
the interface formed by the β-propeller domain of α subunit and I
domain of β subunit (βI) [2].
Integrins at the cell surface undergo drastic structural re-
arrangements from the resting state to the fully activated state
upon stimulation, as elucidated by evidence from electron mi-
croscopy [3–5] and X-ray crystallography [6–10]. The integrins
assume a compact bent form in their resting state which has low
binding afﬁnity to ligands. The intermediate state, with medium
binding afﬁnity to ligands, is by way of a leg extension. Finally, the
swing-out of the hybrid domain of integrin β subunit with respect
to the headpiece converts the integrin to the fully activated state
with high binding afﬁnity to ligands [11].B.V. This is an open access article u
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ntre, Singapore.Extensive mutagenesis studies have shown the contribution of
various regions of the integrin molecule to the structural re-
arrangements associated with activation. Of relevance to this
study, the α1 and α7 helices of the βI domain had shown to
contribute to regulate the integrin activation. The swing-out of the
hybrid domain is triggered by a downward movement of the α7
helix and a corresponding upward movement of α1 helix of βI
domain [5]. More speciﬁcally, the α1 helix of the βI domain un-
dergoes a transformation from a split α1 helix (referred to as the
α1 and α1′ helices) to a continuous helix upon activation [12].
Mutation at the disrupted region of the α1 helix had been shown
to abolish the binding of the αIIbβ3 integrin to the ligand mimic
antibody IgM PAC-1 [13].
We have previously reported the in vitro functional analysis of
a G150D mutation in the integrin β2 subunit in a patient with
leukocyte adhesion deﬁciency 1 (LAD-1) [14]. This missense mu-
tation did not affect the cell surface expression of the αLβ2, αMβ2
and αXβ2 integrins, but their ligand binding activities were totally
abolished under the stimulations with the activating mAb KIM185,
in the presence of Mg/EGTA, or Mn2þ . Structural analysis of the
wild-type (with Gly-150) and mutant (with Asp-150) α1 peptides
by NMR showed that the mutant peptide could not assume a
continuous helical structure as compared to the wild-type peptide.
In this study, we analyzed the effect of the equivalent mutation in
the αIIbβ3 integrin to see if it would affect the integrin without an
αI domain in the same way. Furthermore, we showed that the loss
of adhesion property of the αLβ2 integrin caused by the G150D
mutation may be related to its failure to undergo leg extension
upon Mg/EGTA activation.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Immunoprecipitation of biotin labeled αLβ2 integrin on transfected
HEK293T cells by reporter mAb KIM127. The irrelevant mAb LPM19c (anti-αM) and
heterodimer speciﬁc mAb MHM23 were used as negative and positive control,
respectively.
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2.1. Antibodies and reagents
The hybridoma of mAb MHM23 (β2 integrin heterodimer
speciﬁc) [15] was a gift from Prof. AJ McMichael (John Radcliffe
Hospital, UK). The hybridoma of conformation reporter mAb
KIM127 [16] was kindly provided by Dr. MK Robinson (UCB, Cell-
Tech, UK). mAbs were puriﬁed from respective hybridoma super-
natant using Hi-Trap protein G/A columns (GE Healthcare Life
Sciences). mAb 7E3 (β3 functional blocker) was obtained from
Prof. Barry Coller (Rockefeller University, NY, USA). mAb HIP8
(anti-αIIb mAb) was purchased from eBioscience. FITC-conjugated
sheep anti-mouse IgG and ﬁbrinogen from human plasma were
both purchased from Sigma.
2.2. Plasmids
The pcDNA3.0 expression plasmids carrying αL, αIIb, β2 and β3
cDNA were constructed as previously described [17]. All mutants
were created using SDM (site-directed mutagenesis) method
provided by Stratagen. All mutations were veriﬁed by sequencing
(Axil Scientiﬁc, Singapore). The numbering of amino acids of in-
tegrin subunits started at the initiation methionine.
2.3. Cell culture and transfection
HEK293T (Human embryonic kidney 293T) cells were bought
from ATCC. The cells were maintained in high-glucose DMEM
(Hyclone) supplemented with 10% (v/v) heat-inactivated fetal bo-
vine serum (Gibco), 100 U/ml penicillin and 100 mg/ml strepto-
mycin (Hyclone) at 37 °C incubator with 5% CO2 in air. HEK293T
were transiently transfected with relevant expression plasmids by
PEI (polyethylenimine), as described previously [18].
2.4. Immunoprecipitation
HEK293T transfected with the αLβ2 integrin or its mutants
were labeled with 0.5 mg/ml EZ-link Sulfo-NHS-LC-Biotin (Thermo
Fisher Scientiﬁc) on cells surface. Labeled cells were collected and
incubated with quadruplet conditions: mAb MHM23; mAb
KIM127 with or without αLβ2 activator (Mg/EGTA: 5 mM MgCl2
plus 1.5 mM EGTA); and irrelevant mAb LPM19c for 30 min at
37 °C. After that, cells were washed and lysed in lysis buffer (10
mM Tris, 150 mM NaCl, 0.15 mM CaCl2, 0.5 mM MgCl2, 1% (v/v)
Nonidet P-40, pH 8.0) for 20 min on ice. Cell lysates were in-
cubated with 25% protein-A Sepharose (GE healthcare) beads
which were pre-coated with rabbit anti-mouse IgG (Sigma) for 3 h
at 4 °C. Beads were washed for 3 times. Bound proteins were
eluted and loaded on SDS acrylamide gel under reducing condition
before electroblotting onto PVDF membrane. Blot was incubated
with streptavidin conjugated HRP (GE healthcare) at RT for 1 h
followed by ECL detection method.
2.5. Flow cytometry
Integrin expression at cell surface was described previously
[19]. Brieﬂy, transfected cells were incubated with αIIb speciﬁc
mAb HIP8 on ice for 1 h before labeling with FITC-conjugated IgG.
Negative control was acquired by using an irrelevant primary mAb
(αL speciﬁc). Stained cells were collected by BD FACSCalibur
(BD Biosciences, USA), followed by data plotting using Flowjo
(Tree Star).2.6. Cell adhesion assay
150 ng ﬁbrinogen in bicarbonate buffer (50 mM, pH 9.2) was
coated onto each 96-well followed by incubating at 37 °C for 3–4 h.
1% (w/v) BSA was used to block the non-speciﬁc sites at 37 °C for
0.5 h. Coated plate was washed twice before adding cells. Trans-
fected 293T were labeled by 1 mg/ml BCECF (Invitrogen) at 37 °C
for 20 min, followed by transferring to coated plate and incubating
at 37 °C for 30 min with or without activator (0.5 mM Mn2þ) or
blocker (mAb 7E3). The ﬂuorescence signal which indicates the
ligand-bound cells of each well was measured using a FL600 plate
reader (Bio-Tek instruments, Winooski, USA).
2.7. NMR data collection and structure calculation
23-mer piptides of wildtype and mutant were synthesized by
Peptide Synthesis Core Facility (SBS, NTU). NMR were performed
at 298 K using an Avance II 700 NMR spectrometer with cryogenic
probe as previously described [14]. Brieﬂy, peptide samples were
dissolved in 0.5 mM glucose in PBS at pH 7.4. TOCSY (total corre-
lation spectroscopy) and NOESY (nuclear overhauser effect
spectroscopy) experiments were performed to obtain sequence-
speciﬁc resonances. NOE distance restraints obtained from NOESY
spectra were used for structure calculation. A summary of struc-
ture statistics based on 20 structures can be found in the Sup-
plementary Table 1.3. Results
3.1. G150D mutation in β2 prevents integrin αLβ2 activation via
conformational extension
We have previously shown that the mutation of G150D, found
in a patient with LAD-1, had no effect on the expression of the β2
integrins on transfectants, but the cells were not able to adhere to
ligand coated surfaces in the presence of the activating agents i.e.
Mg/EGTA or the antibody KIM185 [14]. Here we made use of the
reporter antibody KIM127, which was previously shown to bind to
the extended form of αLβ2 integrin [20,21]. In the presence of Mg/
EGTA, KIM127 precipitated the wild-type but not αLβ2-G150D. As
a positive control, the constitutively active mutant αLβ2-N351S
[20] was precipitated by KIM127 even in the absence of Mg/EGTA
(Fig. 1).
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erty of integrin αIIbβ3
Integrin αLβ2 contains an αI domain. To test the functional
generality of this substitution, we also examined the effect of the
corresponding mutation G161D in β3 on the ligand-binding
properties of integrin αIIbβ3 which does not contain an αI domain.
HEK293T cells were transfected with wild-type αIIb and wild-type
β3 or β3-G161D expression plasmids. The G161D mutation did not
affect expression of the αIIbβ3 integrin, but the transfectants were
not able to adhere to ﬁbrinogen coated surfaces even in the pre-
sence of 0.5 mM MnCl2 (Fig. 2).
3.3. The Asp disrupted the helical structure of β3 I domain α1-α1′
helix
We next synthesized two peptides (23-mer) spanning the en-
tire α1 and α1′ helix of the β3 integrin subunit, one representing
the wild type (Gly-161) and the other being mutant G161D. The
structural conformations of the two peptides were analyzed by
NMR. Overlays of the 20 lowest energy conformations of the two
peptides are shown in Supplementary Fig. 1. While the wild-type
peptide is represented by a continuous α-helix in all models, the
mutant peptide exhibits two α-helical stretches separated by aLog Fluorescence Intensity
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Fig. 2. Expression (A) and ﬁbrinogen adhesion (B) of integrin αIIbβ3-G161D
transfectants. (A) Anti-αIIb mAb HIP8 at 10 μg/ml was used to detect the surface
expression of transfected integrins. (B) Mn2þ at 0.5 mM was used to activate the
binding, β3 functional blocking mAb 7E3 was used to establish the adhesion
speciﬁcity.
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Fig. 3. The NMR structures of wild-type β3 peptide spanning the entire α1 and α1′
helices (A) and that of the mutant peptide with G161D (B). The liganded β3 I do-
main structure (C) (extracted from PDB ID: 2VDR) [23], and the un-liganded β3 I
domain structure (D) (extracted from PDB ID: 3FCS) [7]. Residues coordinating
SyMBS were labeled in white, those coordinating MIDAS and ADMIDAS were la-
beled in magenta and yellow respectively.kink at the mutated residue Asp. For clarity, only representative
structures of each of the two peptides are shown in Fig. 3A and B.
The kink of the mutant peptide is supported by several NOEs such
as that between Hb2 of Asp-161 and HN of Leu-164 and that be-
tween the HN of Asp-161 and HN of Leu-164 (Supplementary
Fig. 2A). An equivalent NOE was absent between the HN of Gly-161
and the HN of Leu-164 was absent in the spectra corresponding to
the wild-type β3 peptide (Supplementary Fig. 2B).4. Discussion
Herein, we have extended our study on the effect of the G150D
mutation in β2 on the αLβ2 integrin. The mutant αLβ2 cannot be
immunoprecipitated by the reporter mAb KIM127 in the presence
of Mg/EGTA. The epitope of mAb KIM127 was mapped to the
I-EGF2/3 domain [22], and is not expressed in the bent resting
state but only after activation, e.g. with Mg/EGTA [20]. We have
also included the constitutively active mutant with the N351S
mutation in β2, and it can be immunoprecipitated with KIM127
even in the absence of Mg/EGTA [20].
The glycine (position 150 in β2) is conserved in all β integrin
subunits. We therefore studied the effect of the equivalent muta-
tion in β3 on the αIIbβ3 integrin, an integrin without an αI do-
main. Similar results were obtained, i.e. the G161D mutation in β3
supported αIIbβ3 expression but not adhesion to ﬁbrinogen
coated surfaces. In 2013, Zhang et al. published an extensive study
on the unbending of α1/α1′ as an activation mechanism [13]. A
series of mutants at the G161 was constructed in the β3 integrin,
and the resultant αIIbβ3 integrins showed mixed binding
S. Guan et al. / Biochemistry and Biophysics Reports 7 (2016) 214–217 217properties to the soluble ligand mimetic IgM PAC-1. Interestingly,
the binding activities of all the tested mutants that failed to re-
spond to the activation of 0.2 mM Ca2þ and 2 mM Mn2þ , can be
restored by the introduction of the tail-separation mutant F1030A
or R1032D in the αIIb subunit. However, none of the constructs
contain the G161D mutation. In our hands, we tried to introduce
the constitutively active N351S mutation into the G150D mutant in
the β2 integrin. However, the double mutant cannot be expressed
onto the transfectants’ cell surface (data not shown).
Based on NMR analyses of β3 integrin peptides containing either
Gly-161 (wild-type) or Asp-161 (mutant), the former was re-
presented by a continuous α-helix in all structures (Figure 3A and
Supplementary Figure 1A), the latter exhibited two α-helical stret-
ches separated by a kink at the mutated residue Asp (Figure 3B and
Supplementary Figure 1B). These structures may be compared to
those found in the X-ray crystal structures of the αIIbβ3 integrin. In
the structures of the resting or closed form of β3 integrin (Fig. 3D;
PDB ID: 3FCS), the α1 and α1′ helices are discontinuous and the Gly-
161 is located in between the two α-helical stretches [7]. When the
integrin is bound to the ligand peptide LGGAKQRGDV (Fig. 3C; PDB
ID: 2VDR), the two helices become one continuous α-helix [23]. In-
deed, the same conformation can be induced by three other ligand
peptides HHLGGAKQAGDV (PDB ID: 2VDO), LGGAKQAGDV (PDB ID:
2VDP), and HHLGGAKQRGDV (PDB ID: 2VDQ) [23]. Under physiolo-
gical condition, the α1 and α1′ helices in a full integrin background
has the ﬂexibility to make a transition from discontinuous to con-
tinuous helix in order to facilitate integrin conformational change
from a compact structure to a stretched out one. The mutant peptide,
which may be considered in an “unconstrained” condition, cannot
assume a continuous α-helix. This leads us to hypothesize that the
presence of the Asp in the mutant peptide would lock the integrin in
the resting state. This is one of the many features of the current view
in the overall conformational changes of integrin activation [12].Conﬂict of interest
The authors have declared that no conﬂict of interest exists.Acknowledgements
The work was supported by an Academic Research Fund (AcRF)
RG 93/07 Tier 1 grant and a SUG grant to S.K.A. Law from the
Nanyang Technological University.Appendix A. Transparency document
Transparency document associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.bbrep.2016.06.013.References
[1] R.O. Hynes, Integrins: bidirectional, allosteric signaling machines, Cell 110(2002) 673–687.
[2] T.A. Springer, M.L. Dustin, Integrin inside-out signaling and the immunological
synapse, Curr. Opin. Cell Biol. 24 (2012) 107–115.
[3] N. Nishida, C. Xie, M. Shimaoka, Y.F. Cheng, T. Walz, T.A. Springer, Activation of
leukocyte beta(2) integrins by conversion from bent to extended conforma-
tions, Immunity 25 (2006) 583–594.
[4] J. Takagi, T.A. Springer, Integrin activation and structural rearrangement, Im-
munol. Rev. 186 (2002) 141–163.
[5] T. Xiao, J. Takagi, B.S. Coller, J.H. Wang, T.A. Springer, Structural basis for al-
lostery in integrins and binding to ﬁbrinogen-mimetic therapeutics, Nature
432 (2004) 59–67.
[6] J.P. Xiong, T. Stehle, B. Diefenbach, R.G. Zhang, R. Dunker, D.L. Scott,
A. Joachimiak, S.L. Goodman, M.A. Arnaout, Crystal structure of the extra-
cellular segment of integrin alpha V beta 3, Science 294 (2001) 339–345.
[7] J.H. Zhu, B.H. Luo, T. Xiao, C.Z. Zhang, N. Nishida, T.A. Springer, Structure of a
complete integrin ectodomain in a physiologic resting state and activation and
deactivation by applied forces, Mol. Cell 32 (2008) 849–861.
[8] A.P. Mould, J.A. Askari, S. Barton, A.D. Kline, P.A. McEwan, S.E. Craig, M.
J. Humphries, Integrin activation involves a conformational change in the al-
pha 1 helix of the beta subunit A-domain, J. Biol. Chem. 277 (2002)
19800–19805.
[9] C. Xie, J.H. Zhu, X. Chen, L.Z. Mi, N. Nishida, T.A. Springer, Structure of an in-
tegrin with an alpha I domain, complement receptor type 4, EMBO J. 29 (2010)
666–679.
[10] J.P. Xiong, T. Stehle, R.G. Zhang, A. Joachimiak, M. Frech, S.L. Goodman, M.
A. Arnaout, Crystal structure of the extracellular segment of integrin alpha V
beta 3 in complex with an Arg-Gly-Asp ligand, Science 296 (2002) 151–155.
[11] B.H. Luo, C.V. Carman, T.A. Springer, Structural basis of integrin regulation and
signaling, Annu. Rev. Immunol. 25 (2007) 619–647.
[12] J. Zhu, T.A. Springer, Complete integrin headpiece opening in eight steps, J. Cell
Biol. 201 (2013) 1053–1068.
[13] C.M. Zhang, J.F. Liu, X.L. Jiang, N. Haydar, C. Zhang, H. Shan, J.Q. Zhu, Mod-
ulation of integrin activation and signaling by alpha 1/alpha 1′-helix un-
bending at the junction, J. Cell Sci. 126 (2013) 5735–5747.
[14] S. Guan, S.M. Tan, Y. Li, J. Torres, G. Uzel, L. Xiang, S.K. Law, Characterization of
single amino acid substitutions in the beta2 integrin subunit of patients with
leukocyte adhesion deﬁciency (LAD)-1, Blood Cells, Mol. Dis. 54 (2015)
177–182.
[15] J.E.K. Hildreth, F.M. Gotch, P.D.K. Hildreth, A.J. Mcmichael, A human lympho-
cyte-associated antigen involved in cell-mediated lympholysis, Eur. J. Im-
munol. 13 (1983) 202–208.
[16] M.K. Robinson, D. Andrew, H. Rosen, D. Brown, S. Ortlepp, P. Stephens, E.
C. Butcher, Antibody against the Leu-Cam Beta-Chain (Cd18) promotes both
Lfa-1-dependent and Cr3-dependent adhesion events, J. Immunol. 148 (1992)
1080–1085.
[17] J.M. Shaw, A. Al-Shamkhani, L.A. Boxer, C.D. Buckley, A.W. Dodds, N. Klein, S.
M. Nolan, I. Roberts, D. Roos, S.L. Scarth, D.L. Simmons, S.M. Tan, S.K.A. Law,
Characterization of four CD18 mutants in leucocyte adhesion deﬁcient (LAD)
patients with differential capacities to support expression and function of the
CD11/CD18 integrins LFA-1, Mac-1 and p150,95, Clin. Exp. Immunol. 126
(2001) 311–318.
[18] Y. Durocher, S. Perret, A. Kamen, High-level and high-throughput recombinant
protein production by transient transfection of suspension-growing human
293-EBNA1 cells, Nucleic Acids Res. 30 (2002).
[19] S.M. Tan, R.H. Hyland, A. Al-Shamkhani, W.A. Douglass, J.M. Shaw, S.K.A. Law,
Effect of integrin beta(2) subunit truncations on LFA-1 (CD11a/CD18) and Mac-
1 (CD11b/CD18) assembly, surface expression, and function, J. Immunol. 165
(2000) 2574–2581.
[20] M. Cheng, S.Y. Foo, M.L. Shi, R.H. Tang, L.S. Kong, S.K.A. Law, S.M. Tan, Mutation
of a conserved asparagine in the I-like domain promotes constitutively active
integrins alpha(L)ss(2) and alpha(IIb)ss(3), J. Biol. Chem. 282 (2007)
18225–18232.
[21] X.Y. Tang, Y.F. Li, S.M. Tan, Intercellular adhesion molecule-3 binding of in-
tegrin alpha(L)beta(2) requires both extension and opening of the integrin
headpiece, J. Immunol. 180 (2008) 4793–4804.
[22] C.F. Lu, M. Ferzly, J. Takagi, T.A. Springer, Epitope mapping of antibodies to the
C-terminal region of the integrin beta(2) subunit reveals regions that become
exposed upon receptor activation, J. Immunol. 166 (2001) 5629–5637.
[23] T.A. Springer, J.H. Zhu, T. Xiao, Structural basis for distinctive recognition of
ﬁbrinogen gamma C peptide by the platelet integrin alpha(IIb)beta(3), J. Cell
Biol. 182 (2008) 791–800.
